Vaccines

Maternal vaccination during pregnancy may provide important protection before infants are eligible to receive a vaccine, a study suggests.

The rate of invasive pneumococcal disease in children plummeted by 72% from 2002 to 2021; health care spending in the United States rose 4.1% in 2022 to $4.5 trillion; roughly two-thirds of Americans who have a mental health condition were unable to access treatment in 2021 despite having health insurance.

Growing misinformation around COVID-19 vaccines may have resulted in changes in parents’ trust in vaccines.

Overall, the study authors concluded that the immunogenicity of quadrivalent influenza vaccines (QIV) and trivalent inactivated influenza vaccines (TIV) was similar for common influenza ingredients for children ages 6 to 35 months.

A meta-analysis highlights the potential of influenza vaccination as an adjunctive strategy in reducing cardiovascular disease.

More than 77,000 additional doses of nirsevimab-alip will be distributed for respiratory syndactyl virus (RSV) immunization in infants.

A recent study sheds light on issues surrounding the system's functionality, transparency, and responsiveness.

Researchers provide progression-free survival outcomes for a pancreatic cancer vaccine and safety and efficacy results for a peptide vaccine alone or in combination with pembrolizumab.

Natural infection plus COVID-19 vaccination in pregnant mothers conferred more durable antibody responses in infants than natural infection alone.

The new vaccine program will protect against influenza and COVID-19.

The number of suicides among US military members and their families slightly decreased in 2022; Democratic lawmakers proposed legislation that would require employers to provide paid time off following a pregnancy loss; Pfizer and BioNTech’s flu–COVID-19 vaccine generated a strong immune response against strains of the viruses in an early- to mid-stage trial.

Nirsevimab, a monoclonal antibody used to protect infants from respiratory syncytial virus (RSV), is in limited supply, according to a CDC announcement.

Researchers evaluated the risk of hospitalization for severe flare-ups after vaccination in patients with multiple sclerosis (MS).

During a podcast hosted by Permanente Medicine, Sandra Fryhofer, MD, chair-elect of the Board of Trustees for the American Medical Association and a liaison to the CDC’s Advisory Committee on Immunization Practices, discussed the importance of vaccines for the fall and winter seasons.

Patterns in COVID-19 vaccinations remain largely divided along political party lines, according to one report.

FDA is investigating fraudulent schemes trafficking counterfeit semaglutide (Ozempic); Moderna plans to begin a late-stage trial of its combined COVID-19 and flu vaccine later this year; CMS will begin restricting predictive software used by insurance companies next year.

Katalin Karikó, PhD, and Drew Weissman, MD, PhD, were cited "for their discoveries concerning nucleoside base modifications that enabled the development of effective mRNA vaccines against COVID-19."

This letter discusses COVID-19 vaccine hesitancy and health literacy.

COVID-19 vaccine hesitancy is not associated with health literacy. Personal perception of threat was associated with reduced vaccine hesitancy.

Protection against COVID-19 and vaccine effectiveness increased after receiving 1 or 2 booster doses compared with a primary series alone, but vaccine effectiveness generally declined as the time since last dose increased.

A recent study found that chatbot systems that used artificial intelligence (AI) could be valuable in providing access to current, accurate, and complete information about infectious diseases and vaccines against them.

The Biden administration released the list of 27 Medicare Part B drugs that are subject to rebates back to the government for having price increases that rose faster than inflation as well as the removal of out-of-pocket costs for some vaccines covered under Part D.

In this new study, vaccine efficiency calculations were determined by the amount of heterogeneous and homogenous contact had by vaccinated individuals.

A study of Navy sailors and Marines from the United States found that only 7.7% of participants had neutralizing antibodies for the Omicron variant 8 months after vaccination.

A recent study found that a latent cytomegalovirus infection can have a negative effect on mRNA vaccine responsiveness to COVID-19 infection.